Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has achieved promising results from its Phase 1b clinical trial with azer-cel.
Azer-cel (azercabtagene zapreleucel, is an allogeneic off-the-shelf CD19 CAR T) candidate for patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma (NHL).
All enrolled patients had cancer that had returned following autologous CAR T therapy, a high unmet need for this patient population.
“We are delighted that the first 2 patients in the Cohort B in our azer-cel Phase 1b trial achieved a complete response and continue to maintain their complete responses, one for over 120 days and the other for over 90 days," said Paul Woodard, MD, Imugene’s Chief Medical Officer.
“All four patients enrolled in Cohort B have failed 4 to 5 prior treatments, including autologous CAR T therapy. All four patients remain on the study and given the robust response rates and durability seen to date, we will continue to enrol patients in the azer-cel plus IL-2 cohort and will closely follow all patients for further responses and durability.”
Patients in the trial are being recruited across 15 leading cancer centres in the U.S. including, Columbia University, University of Minnesota, Emory, and Moffitt Cancer Centres and plans are ongoing to open up to five sites in Australia.
